Last reviewed · How we verify
Simvastatin plus clopidogrel
Simvastatin plus clopidogrel is a marketed combination therapy developed by the Federal University of São Paulo, with a key composition patent expiring in 2028. The primary strength of this therapy lies in its unique combination of a statin and an antiplatelet agent, which may offer synergistic benefits for cardiovascular disease management. The primary risk is the potential for increased competition as the key patent expires in 2028, which could lead to generic entries and reduced market share.
At a glance
| Generic name | Simvastatin plus clopidogrel |
|---|---|
| Also known as | Zocor plus Plavix |
| Sponsor | Federal University of São Paulo |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program (NA)
- Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study) (PHASE4)
- Role of Immune Responses After Acute Myocardial Infarction (PHASE4)
- Stenting Versus Best Medical Treatment of Asymptomatic High Grade Carotid Artery Stenosis (NA)
- Efficacy and Safety of Stent Implantation in Symptomatic Extra- and Intracranial Artery Stenosis (NA)
- Assessment of the Lipid Lowering Effect of Rosuvastatin Compared to Atorvastatin in Subjects With Coronary Heart Disease (PHASE4)
- Effects of Omega-3 Fatty Acids on Platelets in Patients With Coronary Artery Disease With Hypertriglyceridemia
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Simvastatin plus clopidogrel CI brief — competitive landscape report
- Simvastatin plus clopidogrel updates RSS · CI watch RSS
- Federal University of São Paulo portfolio CI